Silvant Capital Management LLC Takes $5.46 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY

Silvant Capital Management LLC acquired a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 18,126 shares of the biopharmaceutical company’s stock, valued at approximately $5,456,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. First Horizon Corp boosted its stake in shares of Alnylam Pharmaceuticals by 20.7% in the 4th quarter. First Horizon Corp now owns 163 shares of the biopharmaceutical company’s stock valued at $65,000 after purchasing an additional 28 shares during the last quarter. Daiwa Securities Group Inc. grew its position in shares of Alnylam Pharmaceuticals by 0.3% during the 2nd quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock worth $4,220,000 after buying an additional 35 shares during the period. Golden State Wealth Management LLC raised its stake in shares of Alnylam Pharmaceuticals by 100.0% during the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 36 shares during the last quarter. Coldstream Capital Management Inc. raised its stake in shares of Alnylam Pharmaceuticals by 2.4% during the third quarter. Coldstream Capital Management Inc. now owns 1,640 shares of the biopharmaceutical company’s stock worth $748,000 after buying an additional 38 shares during the last quarter. Finally, Atlantic Union Bankshares Corp lifted its holdings in Alnylam Pharmaceuticals by 20.9% in the fourth quarter. Atlantic Union Bankshares Corp now owns 231 shares of the biopharmaceutical company’s stock valued at $92,000 after buying an additional 40 shares during the period. 92.97% of the stock is owned by institutional investors.

Key Alnylam Pharmaceuticals News

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: BMO Capital Markets upgraded Alnylam to “strong buy”, following its initiation of coverage with an “outperform” rating and a $318 price target. The bullish view could support investor confidence by indicating substantial potential upside from recent trading levels. Benzinga analyst coverage report TickerReport Alnylam coverage

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $299.18, for a total value of $1,145,859.40. Following the completion of the transaction, the director directly owned 1,582 shares of the company’s stock, valued at approximately $473,302.76. The trade was a 70.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals Stock Down 5.5%

Shares of NASDAQ ALNY opened at $229.30 on Friday. Alnylam Pharmaceuticals, Inc. has a 52-week low of $197.81 and a 52-week high of $495.55. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.99 and a current ratio of 3.05. The stock has a market cap of $30.68 billion, a P/E ratio of 42.62 and a beta of 0.30. The firm has a 50 day moving average price of $267.95 and a 200 day moving average price of $297.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, topping analysts’ consensus estimates of $1.63 by $0.21. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The company had revenue of $1.29 billion for the quarter, compared to analysts’ expectations of $1.32 billion. During the same period last year, the firm posted ($0.51) earnings per share. The business’s quarterly revenue was up 66.9% compared to the same quarter last year. Analysts expect that Alnylam Pharmaceuticals, Inc. will post 6.59 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on ALNY. Citigroup reduced their price objective on shares of Alnylam Pharmaceuticals from $380.00 to $340.00 and set a “buy” rating on the stock in a research note on Monday, August 3rd. Wall Street Zen cut shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 2nd. Chardan Capital reissued a “buy” rating and issued a $425.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, July 31st. Barclays reduced their price target on Alnylam Pharmaceuticals from $527.00 to $450.00 and set an “overweight” rating on the stock in a research report on Monday, August 3rd. Finally, Wells Fargo & Company decreased their price objective on Alnylam Pharmaceuticals from $316.00 to $256.00 and set an “equal weight” rating for the company in a research note on Friday, August 14th. Four investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $386.62.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.